SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.4
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$28.05

20 Feb
2025

-0.790

OPEN

$28.07

-2.74%

HIGH

$28.78

1,629,617

LOW

$27.65

TARGET
$28.062

-0.06 change from previous day

 0.0% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 107.4 108.9 xxx
DPS (cps) xxx 106.0 107.3 xxx
EPS Growth xxx - 26.4% 1.4% xxx
DPS Growth xxx 1.9% 1.2% xxx
PE Ratio xxx N/A 25.1 xxx
Dividend Yield xxx N/A 3.9% xxx
Div Pay Ratio(%) xxx 98.7% 98.5% xxx

Dividend yield today if purchased 3 years ago: 2.99%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.87

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx107.4
DPS All xxxxxxxxxxxxxxx106.0
Sales/Revenue xxxxxxxxxxxxxxx8,652.2 M
Book Value Per Share xxxxxxxxxxxxxxx1,648.8
Net Operating Cash Flow xxxxxxxxxxxxxxx1,071.5 M
Net Profit Margin xxxxxxxxxxxxxxx5.91 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx6.53 %
Return on Invested Capital xxxxxxxxxxxxxxx4.59 %
Return on Assets xxxxxxxxxxxxxxx3.53 %
Return on Equity xxxxxxxxxxxxxxx6.53 %
Return on Total Capital xxxxxxxxxxxxxxx4.68 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx101.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx661 M
Long Term Debt xxxxxxxxxxxxxxx3,854 M
Total Debt xxxxxxxxxxxxxxx4,515 M
Goodwill - Gross xxxxxxxxxxxxxxx8,502 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx645 M
Price To Book Value xxxxxxxxxxxxxxx1.60

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx579.5 M
Capex % of Sales xxxxxxxxxxxxxxx6.70 %
Cost of Goods Sold xxxxxxxxxxxxxxx6,604 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,496 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx198 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

21/02/2025

3

Neutral

$29.40

4.81%

Sonic Healthcare reported 1H25 EBITDA growth of 12.3%. UBS comments the US business remains a key concern with organic revenue growth of just 2%.

UBS analysts have maintained a Neutral rating on Sonic Healthcare, lowering the price target to $29.40 from $29.50. Financial forecasts remain largely unchanged, with minor adjustments to reflect stronger performance in the UK and Australia, offset by weaker-than-expected US growth.

Management flagged upcoming changes to Medicare reimbursement rules in Australia, which could impact test volumes, though the full effect remains uncertain. The broker remains cautious on the stock, noting limited near-term catalysts and regulatory uncertainty.

FORECAST
UBS forecasts a full year FY25 dividend of 106.00 cents and EPS of 107.00 cents.
UBS forecasts a full year FY26 dividend of 109.00 cents and EPS of 110.00 cents.

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

19/02/2025

3

Neutral

$29.38

4.74%

Sonic Healthcare had already flagged a robust 1H25 trading update for the four months to October at its AGM, Jarden notes, which has continued on domestically, with Australian Medicare pathology and imaging benefits data up 16% and 10.7% respectively for the six months to December.

With a strong top line already anticipated, the broker expects the focus of the upcoming result to centre on margins.

Sonic has received anti-trust clearance for the LADR acquisition which is now expected to settle on 1 July. Jarden has delayed the contribution of this business to July from April, which drives diluted earnings per share revisions.

Target rises to $29.38 from $29.04, Neutral retained.

FORECAST
Jarden forecasts a full year FY25 dividend of 109.00 cents and EPS of 113.00 cents.
Jarden forecasts a full year FY26 dividend of 119.00 cents and EPS of 145.00 cents.
Access Extra Coverage Research History >

SHL STOCK CHART

FNArena News on SHL

1
FNArena Corporate Results Monitor – 22-02-2025

2:00 PM - Australia
2
Australian Broker Call *Extra* Edition – Feb 19, 2025

Feb 19 2025 - Daily Market Reports
3
Rudi Interviewed: Turning Laggards Into Winners

Feb 17 2025 - Rudi's View
4
Rudi’s View: Hope Trumps Uncertainties

Feb 12 2025 - Rudi's View
5
Rudi’s View: AGL Energy, Bega Cheese, BRG, Harvey Norman, Imdex & Superloop

Feb 06 2025 - Rudi's View

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia